[{"id":"323ff3de-ebe5-4dfb-87f7-504068340771","acronym":"","url":"https://clinicaltrials.gov/study/NCT06138587","created_at":"2023-11-18T22:15:34.208Z","updated_at":"2024-07-02T16:35:17.114Z","phase":"Phase 1","brief_title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT06138587","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Proleukin (aldesleukin) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-02-28"},{"id":"71fc721d-5bad-462d-8429-6b4666cc5367","acronym":"","url":"https://clinicaltrials.gov/study/NCT04024761","created_at":"2021-01-18T19:45:31.523Z","updated_at":"2024-07-02T16:35:20.644Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation","source_id_and_acronym":"NCT04024761","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CIML NK • cyclophosphamide intravenous"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2019","start_date":" 08/31/2019","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-06"},{"id":"dc0e259c-54c3-443d-979e-3cda462cee90","acronym":"","url":"https://clinicaltrials.gov/study/NCT04634435","created_at":"2021-01-19T20:37:11.137Z","updated_at":"2024-07-02T16:35:38.764Z","phase":"Phase 1","brief_title":"Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients","source_id_and_acronym":"NCT04634435","lead_sponsor":"Biohaven Pharmaceuticals, Inc.","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e noraramtide (BHV-1100) • CIML NK"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-08-29"}]